Journal article · 2023 · Open access

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

Viking Huss, Hannah Bower, Karin Engström Hellgren, Thomas Frisell, Johan Askling, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad‐d’Elia, Alf Kastbom, Lars Klareskog and 5 more

Annals of the Rheumatic Diseases, 82(7), 911–919 · Published 8 March 2023 · DOI 10.1136/ard-2022-223636

Open PDFView at the publisherCite this paper

In brief

“Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study” is a 2023 journal article by Viking Huss and 16 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 90 citations as of 19 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
90
Most cited in
2025 (37)
Field-weighted impact
14.48
References
27
Authors
17

Abstract

OBJECTIVE: Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. METHODS: Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi, tumour necrosis factor inhibitors (TNFi) or other (non-TNFi) bDMARDs 2016-2020 using prospectively collected data from the Swedish Rheumatology Quality Register linked to other registers including the Cancer Register. We estimated incidence rates, and HRs via Cox regression, for all cancers excluding non-melanoma skin cancer (NMSC), and for individual cancer types including NMSC. RESULTS: We identified 10 447 patients with RA and 4443 patients with PsA who initiated treatment with JAKi, a non-TNFi bDMARD or a TNFi. Median follow-up times in RA were 1.95, 2.83 and 2.49 years, respectively. In RA, based on 38 incident cancers other than NMSC with JAKi vs 213 with TNFi the overall HR was 0.94 (95% CI 0.65 to 1.38). Based on 59 vs 189 incident NMSC, the HR was 1.39 (95% CI 1.01 to 1.91). At 2 or more years since treatment start, the HR for NMSC was 2.12 (95% CI 1.15 to 3.89). In PsA, based on 5 vs 73 incident cancers other than NMSC, and 8 vs 73 incident NMSC, the corresponding HRs were 1.9 (95% CI 0.7 to 5.2) and 2.1 (95% CI 0.8 to 5.3). CONCLUSION: In clinical practice, the short-term risk of cancer other than NMSC in individuals initiating treatment with JAKi is not higher than for TNFi, but we found evidence of increased risk for NMSC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huss, V., Bower, H., Hellgren, K. E., Frisell, T., Askling, J., Ahlenius, G.-M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad‐d’Elia, H., Kastbom, A., Klareskog, L., Lindqvist, E., Lindström, U., Turesson, C., Sjöwall, C., & Askling, J. (2023). Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Annals of the Rheumatic Diseases, 82(7), 911–919. https://doi.org/10.1136/ard-2022-223636

MLA 9

Huss, Viking, et al. “Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.” Annals of the Rheumatic Diseases, vol. 82, no. 7, 2023, pp. 911–919. https://doi.org/10.1136/ard-2022-223636.

Chicago

Huss, Viking, Hannah Bower, Karin Engström Hellgren, Thomas Frisell, Johan Askling, Gerd-Marie Ahlenius, Eva Baecklund, et al. 2023. “Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.” Annals of the Rheumatic Diseases 82 (7): 911–919. https://doi.org/10.1136/ard-2022-223636.

Harvard

Huss, V. et al. (2023) ‘Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study’, Annals of the Rheumatic Diseases, 82(7), pp. 911–919. doi:10.1136/ard-2022-223636.

IEEE

V. Huss et al., “Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study,” Annals of the Rheumatic Diseases, vol. 82, no. 7, pp. 911–919, 2023, doi: 10.1136/ard-2022-223636.

BibTeX

@article{huss2023cancer,
  title     = {{Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study}},
  author    = {Huss, Viking and Bower, Hannah and Hellgren, Karin Engström and Frisell, Thomas and Askling, Johan and Ahlenius, Gerd-Marie and Baecklund, Eva and Chatzidionysiou, Katerina and Feltelius, Nils and Forsblad‐d’Elia, Helena and Kastbom, Alf and Klareskog, Lars and Lindqvist, Elisabet and Lindström, Ulf and Turesson, Carl and Sjöwall, Christopher and Askling, Johan},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2023},
  volume    = {82},
  number    = {7},
  pages     = {911--919},
  doi       = {10.1136/ard-2022-223636},
  url       = {https://doi.org/10.1136/ard-2022-223636}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202399
20242020
20253737
20262424

Its field-weighted citation impact is 14.48: it has been cited 14.48 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • JAK inhibitors
  • biologic DMARDs
  • rheumatoid arthritis
  • psoriatic arthritis
  • cancer risk
  • non-melanoma skin cancer
  • tumor necrosis factor inhibitors
  • drug safety

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Huss, V., Bower, H., Hellgren, K. E., Frisell, T., Askling, J., Ahlenius, G.-M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad‐d’Elia, H., Kastbom, A., Klareskog, L., Lindqvist, E., Lindström, U., Turesson, C., Sjöwall, C., & Askling, J. (2023). Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Annals of the Rheumatic Diseases, 82(7), 911–919. https://doi.org/10.1136/ard-2022-223636

How many times has this paper been cited?

90 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Viking Huss, Hannah Bower, Karin Engström Hellgren, Thomas Frisell, Johan Askling, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad‐d’Elia, Alf Kastbom, Lars Klareskog and 5 more.

What is the DOI of this paper?

10.1136/ard-2022-223636, permanently at https://doi.org/10.1136/ard-2022-223636. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.